BEONE MEDICINES LTD-ADR (ONC) Stock Price, Quote, News and Overview
NASDAQ:ONC - Nasdaq - US07725L1026 - ADR - Currency: USD
ONC Quote, Performance and Key Statistics
263.78
+7.92 (+3.1%)
The current stock price of ONC is 263.78 USD. In the past month the price increased by 13.7%.
ONC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.42 | 334.13B | ||
| AMGN | AMGEN INC | 13.97 | 155.93B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.57B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.68 | 55.89B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.64B | ||
| ARGX | ARGENX SE - ADR | 101.5 | 35.64B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.20B | ||
| NTRA | NATERA INC | N/A | 22.42B | ||
| BIIB | BIOGEN INC | 8.48 | 19.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.01B | ||
| UTHR | UNITED THERAPEUTICS CORP | 13.1 | 14.81B |
Related stock screener links
About ONC
Company Profile
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Company Info
BEONE MEDICINES LTD-ADR
c/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay
George Town BEIJING KY
Employees: 10473
Phone: 13459494123
BEONE MEDICINES LTD-ADR / ONC FAQ
What is the stock price of BEONE MEDICINES LTD-ADR today?
The current stock price of ONC is 263.78 USD. The price increased by 3.1% in the last trading session.
What is the ticker symbol for BEONE MEDICINES LTD-ADR stock?
The exchange symbol of BEONE MEDICINES LTD-ADR is ONC and it is listed on the Nasdaq exchange.
On which exchange is ONC stock listed?
ONC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BEONE MEDICINES LTD-ADR stock?
12 analysts have analysed ONC and the average price target is 258.23 USD. This implies a price decrease of -2.1% is expected in the next year compared to the current price of 263.78. Check the BEONE MEDICINES LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BEONE MEDICINES LTD-ADR worth?
BEONE MEDICINES LTD-ADR (ONC) has a market capitalization of 28.54B USD. This makes ONC a Large Cap stock.
How many employees does BEONE MEDICINES LTD-ADR have?
BEONE MEDICINES LTD-ADR (ONC) currently has 10473 employees.
What are the support and resistance levels for BEONE MEDICINES LTD-ADR (ONC) stock?
BEONE MEDICINES LTD-ADR (ONC) has a support level at 242.5 and a resistance level at 263.79. Check the full technical report for a detailed analysis of ONC support and resistance levels.
Is BEONE MEDICINES LTD-ADR (ONC) expected to grow?
The Revenue of BEONE MEDICINES LTD-ADR (ONC) is expected to grow by 37.61% in the next year. Check the estimates tab for more information on the ONC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BEONE MEDICINES LTD-ADR (ONC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ONC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ONC, evaluating the profitability, health, valuation and growth aspects
- BEONE MEDICINES LTD-ADR (ONC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BEONE MEDICINES LTD-ADR (ONC) Sales and EPS estimates to see what analysts future expectations are.
- BEONE MEDICINES LTD-ADR (ONC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BEONE MEDICINES LTD-ADR (ONC) Insider and Institutional Ownership to learn about the owners and their transactions.
- BEONE MEDICINES LTD-ADR (ONC) Stock Chart to make your own analysis
- BEONE MEDICINES LTD-ADR (ONC) Latest news and press-releases to stay up to date.
Does BEONE MEDICINES LTD-ADR (ONC) stock pay dividends?
ONC does not pay a dividend.
When does BEONE MEDICINES LTD-ADR (ONC) report earnings?
BEONE MEDICINES LTD-ADR (ONC) will report earnings on 2025-08-05.
What is the Price/Earnings (PE) ratio of BEONE MEDICINES LTD-ADR (ONC)?
The PE ratio for BEONE MEDICINES LTD-ADR (ONC) is 6.75. This is based on the reported non-GAAP earnings per share of 39.09 and the current share price of 263.78 USD. Check the full fundamental report for a full analysis of the valuation metrics for ONC.
What is the Short Interest ratio of BEONE MEDICINES LTD-ADR (ONC) stock?
The outstanding short interest for BEONE MEDICINES LTD-ADR (ONC) is 27.84% of its float. Check the ownership tab for more information on the ONC short interest.
ONC Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ONC.
ONC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ONC. ONC has a bad profitability rating. Also its financial health evaluation is rather negative.
ONC Financial Highlights
Over the last trailing twelve months ONC reported a non-GAAP Earnings per Share(EPS) of 39.09. The EPS increased by 211.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.62% | ||
| ROE | -20.59% | ||
| Debt/Equity | 0.31 |
ONC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ONC. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 109.55% and a revenue growth 37.61% for ONC